Blue Flower

Aram Mangasarian, PhD

Chief Executive Officer

Mr. Mangasarian joined NOXXON in May 2010 as Chief Business Officer of NOXXON. Aram brings over fifteen years' experience in biotechnology and pharmaceutical business development to NOXXON.

Prior to joining NOXXON, Aram served as Vice-President Business Development for Novexel from October 2005 to March 2010. In this capacity he concluded the licensing agreement for North American rights to the NXL104 beta-lactamase inhibitor with Forest Laboratories (NYSE:FRX) in January 2008. Aram was a member of the team that negotiated the acquisition of Novexel by AstraZeneca (NYSE:AZN) in March 2010.

From May 2000 to October 2005, Aram served in a variety of roles at ExonHit Therapeutics (now Diaxonhit, Euronext:ALEHT), eventually heading the business development function as Vice-President. He concluded a number of important agreements for ExonHit, in particular the strategic alliance with Allergan.

Dr. Matthias Baumann

Chief Medical Officer

Dr. Baumann, is a R & D professional with more than 20 years of experience in the healthcare industry. He has a strong background in medical sciences and has worked on a broad range of indications and development approaches for chemical and biotechnological compounds.

Before joining NOXXON, he worked in various management positions with increasing responsibility in the international pharmaceutical and CRO industries.

From 2002 to 2010 he served as Chief Scientific Officer and Managing Director of FOCUS Clinical Drug Development, Neuss/Düsseldorf, Germany, a CRO specialized in early clinical studies and exploratory development. In this role he was responsible for the design and execution of integrated programs progressing development compounds from the preclinical candidate stage to clinical proof of concept.

Before joining FOCUS, Dr. Baumann was with Hoffmann-La Roche, Basel, Switzerland, from 1998 to 2002. As the medical officer of the Integrated Healthcare Solutions group, he was instrumental in the planning and conduct of clinical studies for the qualification of biomarkers and companion diagnostics in various therapeutic areas, e.g. cardiovascular, metabolism and oncology.

Dr. Baumann started his career in the pharmaceutical industry in 1990 at Boehringer Manheim, Mannheim, Germany. Initially he served as a preclinical project manager and pharmacologist for development programs in the field of hematopoietic growth factors and cytokines. From 1993 to 1998 he worked as program manager and department head of the clinical R & D group of Boehringer, dealing with NCEs in osteoporosis and cardiovascular indications and with recombinant growth factors, monoclonal antibodies, gene therapy approaches and medical devices in oncology, infectious diseases and cystic fibrosis.

After receiving his MD degree from the University of Erlangen, Germany in 1984 and before joining the pharmaceutical industry, Dr. Baumann pursued 5 years of postgraduate training in biochemistry and molecular biology at the University of Erlangen, Germany and at the Research Institute of Scripps Clinic, La Jolla, USA. He authored numerous publications in well-recognized, peer-reviewed international journals on topics in oncological and immunological research.

Dr. Baumann joined NOXXON in February 2011 as Chief Medical Officer and Member of the Executive Board.

Jarl Ulf Jungnelius, MD, PhD

Incoming Chief Medical Officer

Jarl Ulf Jungnelius, MD, PhD worked at Celgene from 2007 to 2014 where he served as Vice President of Clinical Research and Development, Solid Tumors.

Prior to that post Dr. Jungnelius held leadership positions at Takeda, Pfizer and Eli Lilly & Company, where he was responsible for clinical development of oncology programs as well as involved in business development. Dr. Jungnelius held important responsibilities in the clinical development of several successful oncology drugs, including Abraxane®, Gemzar®, Alimta® and Revlimid®.

He is an oncologist with more than 25 years of clinical and research experience at both large pharmaceutical companies and academic organizations. Dr. Jungnelius is currently Chief Medical Officer at VAXIMM, Supervisory Board director of Isofol Medical AB, Biovica International AB and Monocl AB and has been a director at Oncopeptides AB since April 2011. He received both a Bachelor of Science degree and his MD from the Karolinska Institute in Stockholm Sweden.